

Dr Javier Martin

Recent publications

Martin J, Samoilovich E, Dunn G, Lackenby A, Feldman E, Heath A, Svirchevskaya E, Cooper G, Yermalovich M, Minor PD. 2002. Isolation of a capsid intertypic poliovirus recombinant from a child with vaccine-associated paralytic poliomyelitis. 2002. *Journal of Virology* 76: 10921-10928

Buttinelli G, Donati V, Fiore S, Marturano J, Plebani A, Balestri P, Soresina AR, Vivarelli R, Delpeyroux F, **Martin J**, and Fiore L. Nucleotide variation in Sabin type 2 poliovirus from an immunodeficient patient with poliomyelitis. 2003. *Journal of General Virology*. 84: 1215-21

Martin J, Crossland G, Wood DJ, Minor PD. Characterisation of formaldehyde-inactivated poliovirus preparations made from live-attenuated strains. 2003. *Journal of General Virology*. 84:1781-8

Deshpande J, van der Avoort H, **Martin J**. Poliovirus type 2 (MEF-1) found in northern India. 2003. *The Polio Lab Network Quarterly Update*. IX: 1-2

Labadie K, Pelletier I, Saulnier A, **Martin J** and Colbere-Garapin, F. Poliovirus mutants excreted by a chronically infected hypogammaglobulinemic patient establish persistent infections in human intestinal cells. 2004. *Virology*. 318(1):66-78

Martin J. Experience with cell sensitivity LQC is reviewed. *Polio Laboratory Network Quarterly Update*. 2004. Volume 3, Issue 3: 1-3

Vinje J, Gregoricus N, **Martin J**, Gary HE Jr, Caceres VM, Venczel L, Macadam A, Dobbins JG, Burns C, Wait D, Ko G, Landaverde M, Kew O, Sobsey MD. Isolation and characterization of circulating type 1 vaccine-derived poliovirus from sewage and stream waters in Hispaniola. 2004. *Journal of Infectious Diseases*. 189: 1168-75

MacLennan CA, Dunn G, Huissoon AP, Kumararatne DS, **Martin J**, O'Leary P, Thompson R, Osman H, Wood D, Minor P and Pillay D. Failure to clear persistent vaccine-derived neurovirulent poliovirus infection from an individual. 2004. *The Lancet*. **363**: 1509-1513

Martin J, Odoom K, Tuite G, Dunn G, Hopewell G, Cooper G, Fitzharris C, Butler K, Hall WW, and Minor PD. Long-term excretion of vaccine-derived poliovirus by a healthy child. 2004. *Journal of Virology*. 78(24):13839-47

Rezapkin G, **Martin J**, and Chumakov K. Analysis of antigenic profiles of inactivated poliovirus vaccine and vaccine-derived polioviruses by Block-ELISA method. 2005. *Biologicals*, 33, 29-39

Berry N, Jenkins A, Davis C, **Martin J**, Wood D, Schild G, Bottiger M, Holmes H, Minor P and Almond N. Mitochondrial DNA and retroviral RNA analyses of archival oral polio vaccine (OPV CHAT) materials: evidence of macaque nuclear sequences confirms substrate identity. 2005. *Vaccine*, 23, 1639-164

Dowdle W, van der Avoort H, de Gourville E, Delpeyroux F, Desphande J, Hovi T, **Martin J**, Pallansch M, Kew O, and Wolff C. 2006. Containment of Polioviruses After Eradication and OPV Cessation: Characterizing Risks to Improve Management. 2006. *Risk Analysis*. 26 (6), 1449–1469

Martin J. Vaccine-derived poliovirus from long term excretors and the end game of polio eradication. 2006. *Biologicals*. 34(2):117-22

Tano Y, Shimizu H, **Martin J**, Nishimura Y, Simizu B, and Miyamura T. Antigenic characterization of a formalin-inactivated poliovirus vaccine derived from live-attenuated Sabin strains. 2007. *Vaccine*. 25(41):7041-6

Andrianarivelo MR, Iber J, Blondel B, Balanant J, Guillot S, Riquet F, **Martin J**, Rousset D, Kew O, and Delpeyroux F. Characterization of two different recombinant lineages of type 2 vaccine-derived poliovirus isolated in Madagascar in 2001-2002. 2007. *PLoS Pathog*. 2007. 3(12):e191

Meisner J, **Martin J**, Szretter K, Li Z, Lee B-J, Langley W, Russell RJ, Katz JM, Steinhauer DA. Infectivity and immunogenicity of influenza virus receptor-site mutants. 2008. *Journal of Virology*. 82(10): 5079-83

Odoom JK, Yunus Z, Dunn G, Minor PD, and **Martin J**. Changes in population dynamics during long-term evolution of Sabin type 1 poliovirus in an immunodeficient patient. 2008. *Journal of Virology*. 2008. 82(18): 9179-90

Martin, J. 2011. Detection and characterization of polioviruses. *Methods Mol Biol*. 665:233-56.

Westdijk, J., D. Brugmans, **Martin, J.**, A. van't Oever, W. A. Bakker, L. Levels, and G. Kersten. 2011. Characterization and standardization of Sabin based inactivated polio vaccine: proposal for a new antigen unit for inactivated polio vaccines. *Vaccine*. 29: 3390-7

Martin, J, C. Milne, P. Minor, K. Chumakov, M. Baca-Estrada, J. F. Caruana, and T. Zhou. 2011. WHO Working Group discussion on revision of the WHO recommendations for the production and control of poliomyelitis vaccines (oral): TRS Nos. 904 and 910. *Vaccine*. 29(38): 6432-6

Gilliland, S.M., Forrest, L., Carre H., Jenkins, A., Berry, N., **Martin, J.**, Minor, P., S. Schepelmann. 2012. Investigation of porcine circovirus contamination in human vaccines. *Biologicals*. 40(4):270-7

Odoom, J.K., L. Forrest, G. Dunn, M. Osei-Kwasi, E. Obodai, J. Arthur-Quarm, J. Barnor, P. D. Minor and **Martin, J**. 2012. Interruption of poliovirus transmission in Ghana: molecular epidemiology of wild-type 1 poliovirus isolated from 1995-2008. *Journal of Infectious Diseases*. 206(7):1111-20

Shulman* LM, Gavrilin* E, Jorba* J, **Martin* J**, Burns* CC, Manor Y, Moran-Gilad J, Sofer D, Hindiyeh MY, Gamzu R, Mendelson E, Grotto I. 2014. Molecular epidemiology of silent introduction and sustained transmission of wild poliovirus type 1, Israel, 2013. *Euro Surveill*. 219(7):20709. (* First author contributors).

Wilton, T., Dunn, G., Eastwood, D., Minor, P.D. and **Martin, J**. 2014. Effect of formaldehyde inactivation on poliovirus. *Journal of Virology*. In press.

Shulman* LM, **Martin* J**, Sofer* D, Burns CC, Manor Y, Hindiyeh M, Gavrilin E, Wilton T, Moran-Gilad J, Gamzo R, Mendelson E, and Grotto U for the GPI group. 2014. Genetic Analysis and Characterization of

Wild Poliovirus Type 1 during Sustained Transmission in a Population with >95% Vaccine Coverage, Israel 2013. *Clinical infectious Diseases*. In press. (* First author contributors).